TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Standard Uranium Retains 100% Unencumbered Ownership of the Sun Dog Project Through Conclusion of Property Option Agreement
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
